Do cats cause schizophrenia?

February 19, 2008

Banked blood shows cat parasite infection precedes schizophrenia onset

Here’s the latest and strongest of the provocative links between toxoplasmosis and behavior change: A case-control study using blood samples taken routinely from members of the U.S. military has shown a strong (P = 0.01) association between Toxoplasma gondii infection and the onset of schizophrenia within six months.

Antibodies to the parasite carried by pet cats were associated with a 26% increase in schizophrenia risk, according to the team from the Walter Reed Army Institute of Research.

This new study strengthens earlier evidence of an association, because of its large numbers and the use of blood samples drawn before diagnosis as well as after.

After using SearchMedica to locate a provocative study, turn to the categories to help decide what you should do next.

Patient Education Materials
What can you say to patients newly concerned about cats? You can use this category to find answers. Try the query Toxoplasma cats, and read the information for pregnant women and HIV patients. (See what the Mayo Clinic article has to say about working in the garden.)

Practical Articles & News
Inform patients that this is not really new, and for now has few practical implications. In this category you’ll find an article suggesting that the cause could just as easily be something caught in preschool, or even something Mom caught. Another reviews the long history of links between infection and mental disorders.


Parkinson relatives shown at high risk of anxiety, depression

January 17, 2008

The risk of anxiety and depression are increased among first-degree relatives of people with Parkinson’s disease. The evidence comes from a huge medical-records database affiliated with the Mayo Clinic.

Is this part of the Parkinson’s spectrum due to genes or to the situation? An epidemiological report like this one in Archives of General Psychiatry can say nothing about the relative contributions of heredity and environment.

Only last October the same group reported increased risk of cognitive impairment and dementia in close relatives of Parkinson’s patients.

Studies about the burden on Parkinson’s caregivers give solid reason to suspect that environment may contribute to mood disorders in the spouse.

Now you’ve learned a little something. Look beyond the main search results to the specific article categories, and know a lot more.

Clinical Trials for Patients
Perhaps entering a clinical trial on the subject might give families a fresh perspective on their situation.

Evidence Based Articles and Meta-Analyses
What are the most effective ways to address the stress on a relative who acts as a caregiver?

Practical Articles & News
What insights can you gain from articles by colleagues who found ways to help these families cope?


NCI breast-cancer analysis shows that risks are not colorblind

December 12, 2007

A report in JNCI unveils a model of breast-cancer risk assessment created specifically for African-American women. Based in part on data from the Women’s Contraceptive and Reproductive Experience (CARE) study, the new CARE model shows that 30% of African-American women should have qualified for the STAR trial of breast cancer prevention. That protocol used the standard NCI Breast Cancer Risk Assessment Tool (BRCAT), which judged only 15% eligible.

The new tool is not recommended for women who have BRCA mutations or a history of breast cancer.

Last July, Howard University researchers reported that a modified version of the BCRAT (or Gail model) was even worse at predicting risk in this population than the original Gail model itself.

A meta-analysis in JCO last year revealed that African-Americans have poorer outcomes from breast cancer treatment irrespective of socioeconomic factors. Risk counseling based on erroneous assessment must be among the reasons.

See what else you can find in the categories that sort your results by document type:

Clinical Trials for Patients
Learn more about the CARE study assessing breast cancer risk among white and African American women.

Practical Articles and News
Locate the Gail model itself on the National Cancer Institute website. (The new CARE model isn’t there yet. The NCI says it will be there shortly.)


FDA reviewing Chantix suicide risk

December 4, 2007

New smoking cessation drug linked with suicide ideation

As well as acne and depression, add smoking to the conditions whose medical treatment may cause suicidal thoughts. The FDA is assessing postmarketing reports that mood changes may accompany use of varenicline (Chantix). Some Chantix users reporting suicidal thoughts had no prior history of psychological issues.

A study published last month hints at a genetic basis underlying this adverse reaction to some medications. Maybe someday there will be a test for this particular drug hazard.

Is Chantix more effective than Zyban (bupropion)? It still isn’t settled.

SearchMedica organizes the results into clinically useful categories to speed your search for relevant information:

Clinical Trials for Patients
New clinical trials are testing the potential of the MAOI antidepressant selegiline for smoking cessation.

Practical Articles and News
An FDA document (written for people taking the antidepressant SSRIs also linked with suicidal thoughts) suggests ways to recognize and address the problem in yourself or a family member.


Vaccines Work Longer than Previously Thought

November 29, 2007

Long-term study raises questions about need for booster shots

Analyzing regular blood samples taken over 26 years from health employees at a primate research center, an Oregon team has found that most vaccines remain potent far longer than thought – with response half-lives often lasting longer than a century.

Of the viral disorders, varicella had the shortest half-life, at only 50 years. Only tetanus and diphtheria had half-lives shorter than 20 years.

Keep your eyes open for newer research that spurs a change in guidelines regarding booster shots.

See how SearchMedica categories allow you to hone in on specific questions:

Evidence Based Articles and Meta-Analyses
Find the studies that lay to rest the old allegation that vaccines cause autism.

Practice Guidelines
Refresh yourselves on the latest standards for use of the new varicella vaccine.


FDA approves Abilify for adolescents with schizophrenia

November 27, 2007

Based on the recent multinational study showing a significant benefit for adolescents with schizophrenia, the FDA has approved aripirazole (Abilify) for kids aged 13 to 17. The study showed significant improvements over placebo, and a discontinuation rate of only about 4% over six weeks.

In that clinical study involving more than 300 adolescents in 13 countries, the most common side effects were extrapyramidal symptoms and drowsiness. About 5% of the teens gained at least 7% over their baseline weight.

The action closely follows approval of risperidone for kids with schizophrenia only two months ago.

Learn more quickly with SearchMedica’s content categories:

Practical Articles and News
Find guidance for encouraging adherence despite body-image issues in young schizophrenia patients.

Clinical Trials for Patients
A new clinical trial (but not for adolescents) is comparing Abilify head-to-head with injectable Risperdal to test the effects on adherence. (The hypothesis favors Risperdal).


NSAIDs May Prevent Parkinson’s

November 19, 2007

People who regularly took nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin for at least a month were significantly less likely to develop Parkinson’s disease in the following two years, according to a study just published in Neurology.

Association does not equal causation, but the study adds to growing evidence that implicates neuroinflammation in Parkinson’s.

Recently a trial was suspended when NSAIDs showed no protective effect against Alzheimer’s.

Refine Your Search

Patient Education Materials
For someone eager to start prophylaxis now, point out that the strategy is not proven and offer information about side effects that they can take home and read later.

Clinical Trials for Patients
No clinical trials are underway to test this possibility. But one that was completed in October is assessing brain markers of inflammation in Parkinson’s and similar disorders.


Cognitive, light therapy work against SAD

November 12, 2007

Improving treatment for the seasonally sad

The clocks change again, and people with seasonal affective disorder brace themselves. What’s new for these patients since last autumn? For one thing, a new study hints that cognitive therapy might boost the effects of light treatment.

A new multicenter trial shows that a more targeted LED light source may work better than the large full-spectrum lamps.

Clinical Trials for Patients
The new LED light and other strategies are being tested in numerous new clinical trials involving SAD.

Alternative Medicine
Your patient might like to know that the National Institutes of Health endorse light therapy for SAD as an example of “veritable energy medicine”.


More zinc equals less pneumonia

November 8, 2007

In nursing home (at least), boosting zinc lowers pneumonia risks.

In a study of nursing home residents enrolled in a nutrition trial, those with serum zinc at or above normal levels (70 microg/dL) had less severe pneumonia and were less likely to die of it. The study was published in Oct. 2007 by the American Journal of Clinical Nutrition.

Does this justify recommending zinc supplements for your older patients living at home? Probably not. Another recent study showed that multivitamin and mineral supplements had no effect on the course of infections among elderly individuals in the community.

Clinical Trials for Patients
Clinical researchers are currently paying more attention to zinc and pneumonia in malnourished children.

Evidence Based Articles and Meta-analyses
What is the evidence that zinc lozenges shorten the course of a common cold?


Hepatitis A Vaccine Better than Immune Globulin

November 1, 2007

Given after exposure, the hepatitis A vaccine provides as much protection against hepatitis A as immune globulin, according to a new randomized study in the New England Journal of Medicine. An accompanying editorial says the vaccine may be preferable to the immune globulin. It is no more expensive, easier to administer, more widely available, and effective longer.

The study validates new recommendations from the CDC issued last June. Those at high risk of liver disease after contracting HepA—people under one year old or older than 40 and those with chronic liver disease—should still receive immune globulin.

The number of hepatitis A cases in the US plummeted to less than 4,000 last year, thanks to herd immunity after introduction of the vaccine.

Practical Articles and News
What are the contraindications to using this vaccine?

Practice Management
What are the CPT codes for hepatitis A?